New biotechnology company formedAstraZeneca and Nomura Phase4 Ventures announce creation
of new company “Albireo” AstraZeneca and Nomura Phase4 Ventures have announced the signing of a deal to form Albireo, a biotechnology company focused on developing new treatments for gastrointestinal (GI) disorders. The spinout is a result of AstraZeneca's previously announced strategic decision to concentrate on Nexiam and internal GI research focussed on Gastroesophageal Reflux Disease (GORD). “Albireo represents an exciting opportunity for AstraZeneca to deliver value for patients and our shareholders,” said John Goddard, Senior Vice President, AstraZeneca Strategic Planning and Business Development. AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the world's leading pharmaceutical companies with a broad range of products in seven therapeutic areas, including gastrointestinal, cardiovascular, neuroscience, respiratory, oncology, pain and anaesthesia and infection. Editorial contact Melanie Stevens (Nee Letcher) |